Viral Latency: The Silent Phase Before Reactivation
Latency is a reversible, non-replicative state where viral genome persists in host cells without producing infectious virions.
Key Features
- Genome maintenance: Episomal (herpesviruses) or integrated (retroviruses).
- Minimal gene expression: Latency-associated transcripts (LATs) only; no structural proteins.
- Immune evasion: No viral antigens presented → invisible to CTLs.
- Specific reservoirs: HSV → trigeminal/sacral ganglia; VZV → dorsal root ganglia; EBV → memory B cells; HIV → resting CD4+ T cells; CMV → myeloid progenitors.
Reactivation Triggers
- Immunosuppression (steroids, chemo, HIV, transplant).
- Stress (cortisol, catecholamines).
- UV radiation (HSV).
- Hormonal changes.
- Co-infections, inflammation.
Clinical Consequences
- Herpes: cold sores, shingles, encephalitis.
- EBV: PTLD, lymphomas.
- CMV: end-organ disease in transplant.
- HIV: viral rebound if ART stopped.
- BK virus: nephropathy in kidney transplant.
Therapeutic Implications
- Antivirals target lytic replication (not latent genome).
- ART suppresses HIV but doesn't eradicate reservoir.
- Latency-reversing agents ("shock and kill") experimental for HIV cure.
Latency = persistence strategy. Understanding it is key to cure research and managing reactivation risk.
Viral Infections - Related Articles
- Viral Meningitis: Causes, Symptoms & Risk Factors
- Ebola Virus Disease: Comprehensive Guide to Transmission, Symptoms, and Prevention
- Scabies Transmission: How It Spreads (And What Doesn't)
- Rhinovirus Discovery: First Isolation in 1956
- Stomach Virus (Gastroenteritis) Trends: Surveillance and Prevention
- Chicken Pox in Infants: Symptoms, Treatment & What to Expect
- A Family's Journey Through COVID-19 Loss and Resilience
